Patrick Hwu: Can neoantigen-specific TILs improve immunotherapy for gastrointestinal cancers?
Patrick Hwu, President and CEO of Moffitt Cancer Center, shared a shared a post on LinkedIn:
“New landmark research out today on TIL Therapy for GI cancers
Can neoantigen-specific tumor-infiltrating lymphocytes (TILs) improve immunotherapy for gastrointestinal cancers?
In this study, published in Nature Magazine, Lowery, et al. National Cancer Institute (NCI) found that expanding TILs that recognize patient-specific tumor mutations can enhance the immune response against cancer. When combined with anti-PD1, the response rate was 23 percent in patients with GI cancers.
Early findings suggest this approach could improve outcomes for patients who do not respond well to current immunotherapies. Personalized TIL could be an important tool in the fight against gastrointestinal cancers!
Here’s a link to the full study.”
Neoantigen-specific tumor-infiltrating lymphocytes in gastrointestinal cancers: a phase 2 trial
Authors: Frank J. Lowery et al.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023